NEXEMPA L 25 | 5

NEXEMPA L 25 | 5 combines the glucose-lowering benefits of Empagliflozin and Linagliptin to provide a powerful treatment option for patients with type 2 diabetes. This fixed-dose combination helps control blood sugar levels effectively while reducing the risk of complications associated with uncontrolled diabetes.

COMPOSITION: Empagliflozin 25 mg + Linagliptin 5 mg

MODE OF ACTION:

• Empagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, leading to increased glucose excretion through urine and a reduction in blood glucose levels.
• Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which prolongs the activity of incretin hormones, enhancing glucose-dependent insulin secretion and reducing glucagon secretion.

INDICATIONS:

• Management of type 2 diabetes mellitus in adults to improve glycemic control.
• As adjunct therapy to diet and exercise, when monotherapy does not achieve adequate glycemic control.

DOSAGE:

• The recommended dose is 1 tablet once daily, taken in the morning, with or without food.
• Dose adjustments may be necessary based on renal function and clinical response.

STORAGE: Store at room temperature not exceeding 25ᵒC, protected from moisture and light.

DISCLAIMER: This information is intended for medical professionals and registered medical practitioners only. Use of this product should be under the supervision of a registered medical practitioner with a valid prescription.